<DOC>
	<DOCNO>NCT02350686</DOCNO>
	<brief_summary>Phase II study second line capecitabine plus oxaliplatin ( XELOX ) patient advance biliary tract carcinoma failure gemcitabine-based chemotherapy .</brief_summary>
	<brief_title>XELOX Advanced Biliary Tract Carcinoma After Failure Gemcitabine-based Chemotherapy</brief_title>
	<detailed_description>XELOX - Xeloda , 1000mg/㎡ bid , day 1-15 , every 3 week - Oxaliplatin 130mg/㎡ , day 1 , every 3 week Until disease progression , patient 's refusal 8 cycle ( maximum ) .</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1. age ≥ 18 2. histologically cytologically confirm adenocarcinoma biliary tract ( intrahepatic , extrahepatic cholangiocarcinoma , gall bladder cancer ampulla Vater cancer ) 3. unresectable metastatic 4. progression treatment first line gemcitabinebased chemotherapy 5 . ECOG performance status 0~2 6. measurable evaluable lesion per RECIST 1.1 criterion 7. adequate marrow , hepatic , renal cardiac function 1. severe comorbid illness active infection 2. pregnant lactate woman 3 . History document congestive heart failure , angina pectoris require medication , evidence tranasmural myocardial infarction ECG , poorly control hypertension , clinically significant valvular heart disease high risk uncontrollable arrhythmia 4. active CNS metastasis controllable radiotherapy corticosteroid 5. known history hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>